POstmastectomy radioThErapy in Node-posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial.

Abstract

BACKGROUND:

Various randomized trials have demonstrated that postmastectomy radiotherapy (RT) to the chest wall and comprehensive regional nodal areas improves survival in patients with axillary node-positive breast cancer. Controversy exists as to whether the internal mammary node (IMN) region is an essential component of regional nodal irradiation. Available data on the survival benefit of IMN irradiation (IMNI) are conflicting. The patient populations enrolled in previous studies were heterogeneous and most studies were conducted before modern systemic treatment and three-dimensional (3D) radiotherapy (RT) techniques were introduced. This study aims to assess the efficacy and safety of IMNI in the context of modern systemic treatment and computed tomography (CT)-based RT planning techniques.

METHODS:

POTENTIAL is a prospective, multicenter, open-label, parallel, phase III, randomized controlled trial investigating whether IMNI improves disease-free survival (DFS) in high-risk breast cancer with positive axillary nodes (pN+) after mastectomy. A total of 1800 patients will be randomly assigned in a 1:1 ratio to receive IMNI or not. All patients are required to receive ≥ six cycles of anthracycline and/or taxane-based chemotherapy. Randomization will be stratified by institution, tumor location (medial/central vs. other quadrants), the number of positive axillary nodes (1-3 vs. 4-9 vs. ≥10), and neoadjuvant chemotherapy (yes vs. no). Treatment will be delivered with CT-based 3D RT techniques, including 3D conformal RT, intensity-modulated RT, or volumetric modulated arc therapy. The prescribed dose is 50 Gy in 25 fractions or 43.5 Gy in 15 fractions. Tiered RT quality assurance is required. After RT, patients will be followed up at regular intervals. Oncological and toxilogical outcomes, especially cardiac toxicities, will be assessed.

DISCUSSION:

This trial design is intended to overcome the limitations of previous prospective studies by recruiting patients with pN+ breast cancer, using DFS as the primary endpoint, and prospectively assessing cardiac toxicities and requiring RT quality assurance. The results of this study will provide high-level evidence for elective IMNI in patients with breast cancer after mastectomy.

TRIAL REGISTRATION:

ClinicalTrails.gov , NCT04320979 . Registered 25 Match 2020, https://clinicaltrials.gov/ct2/show/NCT04320979.

• Authors: Xu-Ran Zhao, Hui Fang, Yu Tang, Zhi-Hui Hu, Hao Jing, Lin Liang, Xue-Na Yan, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Bo Chen, Yuan Tang, Shu-Nan Qi, Ning Li, Ning-Ning Lu, Kuo Men, Chen Hu, Yu-Hui Zhang, Ye-Xiong Li, Shu-Lian Wang
• Journal: BMC cancer (BMC Cancer) Vol. 21 Issue 1 Pg. 1185 (Nov 06 2021) ISSN: 1471-2407 [Electronic] England
• PMID: 34742270 (Publication Type: Clinical Trial Protocol, Journal Article)
• Copyright: © 2021. The Author(s).

Chemical References

• Anthracyclines
• Antineoplastic Agents
• Bridged-Ring Compounds
• taxane
• Taxoids

Topics

• Female
• Humans
• Anthracyclines (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Axilla
• Breast Neoplasms (diagnostic imaging, pathology, radiotherapy, therapy)
• Bridged-Ring Compounds (therapeutic use)
• Disease-Free Survival
• Dose Fractionation, Radiation
• Lymphatic Irradiation
• Lymphatic Metastasis (diagnostic imaging, radiotherapy)
• Mastectomy
• Postoperative Care (methods)
• Prospective Studies
• Radiotherapy Planning, Computer-Assisted
• Radiotherapy, Conformal (methods)
• Taxoids (therapeutic use)
• Tomography, X-Ray Computed
• Multicenter Studies as Topic
• Clinical Trials, Phase III as Topic
• Randomized Controlled Trials as Topic